In this study, our group at the Johns Hopkins Kimmel Cancer Center demonstrated that a minimally invasive blood test effectively captures early responses to immunotherapy in patients with advanced lung cancer. By measuring circulating tumor DNA (ctDNA) levels, this liquid biopsy approach provides monitoring of therapy response with molecular precision and predicts survival. This advancement holds great potential for molecular response-adaptive treatment decision-making.
To gain a deeper insight, view the following video, “Capturing Immunotherapy Response in a Blood Drop”.